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Abstract
Background: Chronic fatigue syndrome (CFS) is characterized by profound and disabling fatigue with no known
somatic explanation. Cognitive behavioral therapy (CBT) has proven to be a successful intervention leading to a
reduction in fatigue and disability. Based on previous neuroimaging findings, it has been suggested that central
neural mechanisms may underlie CFS symptoms and play a role in the change brought on by CBT. In this
randomized controlled trial we aim to further investigate the neural mechanisms that underlie fatigue in CFS
and their change by CBT.
Methods/Design: We will conduct a randomized controlled trial in which we collect anatomical and functional
magnetic resonance imaging (MRI) measures from female CFS patients before and after CBT (N = 60) or waiting
list (N = 30) and compare these with measures from age and education matched healthy controls (N = 30). By
including a large treatment group we will also be able to compare patients that benefit from CBT with those
that do not. In addition, to further investigate the role of endocrine and immune biomarkers in CFS, we will
determine cortisol and cytokine concentrations in blood, hair and/or saliva.
Discussion: This project creates an unique opportunity to enhance our understanding of CFS symptoms and its
change by CBT in terms of neuroanatomical, neurofunctional, endocrinological and immunological mechanisms
and can help to further improve future treatments strategies.
Trial registration: Dutch Trial Register #15852. Registered 9 December 2013 (http://www.trialregister.nl/trialreg/
admin/rctview.asp?TC=4311)
Keywords: Chronic fatigue syndrome, Cognitive behavioral therapy, MRI
Background
Chronic fatigue syndrome (CFS) is characterized by
severe fatigue persisting at least 6 months and leading to
considerable impairment in daily functioning ([1];
Reeves et al., [2]). Various accompanying symptoms may
be present, such as joint and muscle pain, headaches,
impaired memory and concentration, and exercise in-
tolerance. The aetiology of CFS is currently unknown;
symptoms are not explained by a known medical condi-
tion and are not alleviated by rest (Prins et al., [3]).
Cognitive behavioral therapy (CBT) for CFS, a treatment
that aims to change behavior and cognitions thought to
perpetuate symptoms, has shown to be an effective
treatment for CFS patients [4]. Following treatment, the
majority of CFS patients show improvement in symp-
toms and a subgroup even fully recovers from CFS
(Knoop et al., [5]; White et al., [6]).
Little is known about the mechanism of change of
CBT for CFS. Thus far, mediation analysis of randomized
controlled trials testing the efficacy of CBT suggested
that the reduction of fatigue and disability is mediated
by a change in cognitions, such as decreased focusing on
symptoms and changes in illness beliefs ([7]; Knoop et
al., [8]; Wiborg et al., [9]; Wiborg et al., [10]), rather than
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changes in physical fitness ([7]; Wiborg et al., [11]).
These findings implicate that neural mechanisms under-
lying these cognitions may play an important role in
CFS. This suggestion is further supported by accumulat-
ing evidence from neuroimaging studies demonstrating
neural abnormalities in CFS patients [12]. Thus, several
neuro imaging studies have found reduced grey matter
volumes ([13, 14]; Okada et al., [15]), white matter
changes (Zeineh et al., [16]). and functional abnormal-
ities in prefrontal, parietal, and limbic regions for CFS
patients versus healthy controls ([17–20]; Lange et al.,
[21]). In addition, a recent positron emision tomography
(PET) study demonstrated increases in microglia activity,
suggestive for neuroinflammation (Nakatomi et al., [22]).
Moreover, one neuroimaging study also demonstrated
that treatment of CFS with CBT increased grey matter
volume in CFS patients. These changes were located in
the dorsolateral prefrontal cortex (DLPFC) [14], a region
associated with cognitive-regulatory functions. Similarly,
CBT-related anatomical and functional changes have
been reported in other conditions such as chronic pain
(Seminowicz et al., [23]) and mood and anxiety disorders
(Beauregard, [24, 25]; Strauman et al., [23]). Accordingly,
we suggest that a reduction in fatigue and disability
brought on by CBT for CFS is accompanied and possibly
mediated by anatomical and functional changes in the
brain.
So far, definitive evidence for this argument is limited
because the few existing studies have often used small
samples sizes and lacked a patient control group. The
inclusion of a patient control condition is necessary to
attribute changes seen in the treatment group to the
intervention, rather than to time per se or to changes
occurring irrespective of the treatment. In this study we
will address these issues and aim to further investigate
neural mechanisms underlying CFS and its change by
CBT using anatomical and functional magnetic reson-
ance imaging (MRI) in a large-sample randomized
controlled trial (RCT). In this RCT, we will compare
changes between CFS patients that had CBT (N = 60)
with patients that were allocated to a waiting period (N
= 30). By including the large treatment group we will
also be able to investigate the relationship between
neural changes and treatment response. Patients will be
compared with healthy controls (N = 30) who are also
tested twice, separated by 6 months, to control for test-
retest effects.
This study will investigate neural mechanisms under-
lying CFS symptoms and its changes after CBT. The
aims are threefold. First, we aim to replicate previous
found anatomical CBT-related changes in grey matter
volumes [14] using anatomical MRI and qualify these
findings by exploring changes in metabolite concentra-
tions and white matter integrity using magnetic resonance
spectroscopy (MRS) and diffusion tensor imaging (DTI).
Second, we aim to explore the mechanisms of change of
CBT for CFS using functional MRI (fMRI) and behavioral
testing. Finally, we aim to investigate immune and endo-
crine functioning in CFS and its change after CBT by
assessing various biomarkers in blood, saliva and hair.
These three aims are discussed in more detail below.
Anatomical changes in CFS
Our first aim is to replicate and extend previous found
anatomical changes in grey matter volumes [14] by in-
cluding a larger treatment group and a patient control
group. Furthermore, we aim to provide additional infor-
mation about the nature of anatomical changes by
exploring changes in metabolite concentrations using
magnetic resonance spectroscopy (MRS) and white mat-
ter integrity using diffusion tensor imaging (DTI).
MRS allows for the identification and quantification of
various metabolites in the brain like N-acetylaspartate
(NAA), myo-inositol, choline, creatine glutamate/glutamine.
These metabolite concentrations can inform us about the
nature of grey matter changes. For example, while NAA is
mainly present in the neurons and provides a marker of
neuronal health (Moffett et al., [26]), myo-inositol is
mainly associated with glia-activation and provides a
marker of neuroinflammation [27]. Previous work in small
samples of CFS patients (N < 11) has reported reduced
NAA levels in the hippocampus [28] as well as increased
choline/creatine ratios in the occipital cortex (Puri et al.,
[29]), prefrontal cortex (Tomoda et al., [30]) and basal
ganglia (Chaudhuri and Behan, [31]) , compared with
healthy controls. Similarly, alterations in MRS measures
have been reported in other medically unexplained condi-
tions such as chronic pain (see review (Harris and Clauw,
[32])) and irritable bowel syndrome (Niddam et al., [33]).
MRS measures have shown to vary as a function of pain
sensitivity ([34]; Petrou et al., [35]) or pain catastrophizing
([36]; Niddam et al., [33]). Moreover, some pilot studies
show that NAA levels are subject to change following be-
havioral therapies [37] (O’Neill et al., [38]; Zurowski et al.,
[39]) suggesting that NAA reductions are reversible and
can be used to monitor treatment response. In this pro-
ject, we will investigate CBT-related metabolite changes in
the DLPFC, as our aim is to assess the nature of previ-
ously reported grey matter changes in this region [14].
However, given that previous studies in CFS found metab-
olite differences in various brain regions, regional specifi-
city to the DLPFC will be investigated by comparing
changes in the DLPFC with those in the occipital cortex.
DTI is a technique that is sensitive to microstructural
organization of neural tissues, measuring both the direc-
tionality and the magnitude of water diffusion (Beaulieu,
[40]). To our knowledge, only one study has used DTI
to investigate white matter in a small sample of CFS
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patients (N = 15) and report increased fractional anisot-
ropy (FA) values in CFS patients compared with healthy
controls in the right arcuate fasciculus, a white matter
pathway that connects the frontal lobe with the inferior
parietal lobe (Zeineh et al., [16]). In this project we will
assess DTI measures in a larger sample and also explore
possible changes after CBT.
Functional changes in CFS
Our second aim is to explore the mechanisms of change
of CBT for CFS by means of functional MRI and behav-
ior. Task-dependent functional neuroimaging provides
information about neural mechanisms that underlie
specific processes involved in the execution of a specific
task. Accordingly, task selection should always be done
against the background of relevant cognitive and neural
models of the disorder ([12]; Strauman et al., [23]). For
this project, task-selection was based on a combination
of a neurobiologically informed Bayesian model of
somatoform symptoms [41] and clinical observations.
The recently developed Bayesian model describes
somatoform symptoms in terms of altered perception
resulting from an inference failure between sensory in-
formation and prior beliefs [41]. In the light of CFS,
the model suggests that increased perception of symp-
toms may arise from pathologically precise prior be-
liefs that affect sensory perceptions and attributions.
This model exploits some key factors that have been
identified by clinical cognitive behavioral models of
CFS and that are challenged by CBT for CFS including
the role of fatigue related beliefs (e.g. about the ability
to engage in physical activities) and the attention
towards symptoms ([7]; Knoop et al., [8]; Vercoulen
et al., [42]; Wiborg et al., [9]). In addition, clinical ob-
servations demonstrate that symptoms often involve
physical activities. Thus, CFS patients show reduced
activity levels (Nijs et al., [43]; Werf et al., [44]) and
underperformance on physical exercise tasks (Fry and
Martin, [45]; Riley et al., [46]; Schillings et al., [47]).
These decreases in physical activities are suggested to
result from reduced expectations about physical abil-
ities (Heins et al., [48]; Nijs et al., [49]), fear avoidance
beliefs (e.g. the fear that exercise will make symptoms
worse) and avoidance behaviors, which are highly
prevalent in the CFS population ([50]; Nijs et al., [51]).
Indeed, a recent clinical trial revealed that changes in
fear avoidance beliefs and avoidance behavior mediate
the CBT effects in CFS patients [7]. Following the
neurobiological informed model and these clinical ob-
servations, we aim to investigate neural mechanisms
underlying inference processes during effortful phys-
ical exertions using two fMRI paradigms. In addition,
we will also explore general inference processing in the
visual domain using a behavioral paradigm.
In the first fMRI paradigm we will investigate effort
perception during an effort task, using a MR-compatible
handgrip device. Neural activity will be assessed during
preparation of low, medium and high effort production
and in response to task-feedback indicating that the sub-
jects provided too much, too little or the correct amount
of effort. Previous work has already demonstrated that
CFS patients show alterations in neural error processing
during a motor imagery task [20]. This study will extend
these findings by testing whether alterations in motor
preparation and error processing are consistent with the
known fatigue-related beliefs. To this end, we will test
the hypothesis that CFS patients show alterations in
neural feedback-processing towards errors that indicate
that too little versus too much physical effort has been
produced and that these alterations vary as a function of
effort level. We hypothesize that successful CBT outcome
is accompanied by normalization of these alterations.
In the second fMRI task we aim to investigate alter-
ations in neural processes underlying effort avoidance
learning. CFS has been associated with increased avoid-
ance of physical activities (see above). However, it is un-
clear whether these avoidance behaviors are due to the
increased experienced effort of physical activities or
whether CFS patients develop dysfunctional beliefs about
the need to avoid physical activities. We will assess neural
mechanisms underlying the inferring of contingencies be-
tween cues and effortful handgrip-contractions, using an
adapted version of the salience attribution task (Roiser
et al., [52]; Roiser et al., [53]). This task allows for dissoci-
ating avoidance learning that is adaptive, i.e. developing
avoidance only for cues that are predictive for effortful
outcomes, from avoidance learning that is non-adaptive,
i.e. developing dysfunctional avoidance, also for cues that
are not predictive for effortful outcomes. We will test two
hypotheses: 1) CFS patients will show increased adaptive
avoidance learning compared to healthy controls, which is
suggestive of an increased impact of the experienced effort
on avoidance learning. 2) CFS patients will show increased
non-adaptive avoidance learning, which is suggestive of a
higher tendency to develop dysfunctional expectations for
cues that are not predictive for effortful outcomes. We
hypothesize that successful CBT is accompanied by
normalization of (non-) adaptive avoidance learning.
In the behavioral task we aim to investigate general
inference processes in CFS patients. The Bayesian model
suggests that the perception of medically unexplained
symptoms result from prior beliefs that are afforded too
much precision. Thus, an increased general tendency to
base perceptual decisions more on prior information
than on sensory inputs in any sensory domain may reflect
a fundamental vulnerability that may predispose subjects
to develop CFS. Here we aim to test this hypothesis in the
visual domain by investigating the influence of informative
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cues on decisions about the direction of moving dots
using the well developed moving dot paradigm (Rahnev
et al., [54]).
Immune and endocrine changes in CFS
Finally, we aim to investigate immune and endocrine
changes in CFS. Cytokines are small proteins that play
a key role in normal physiology and disease. Because
of the resemblance of CFS symptoms with so called
“sickness behavior” including the symptoms fatigue,
post-exertional malaise and reduced activity levels,
CFS has often been suggested to involve increased
activity of pro-inflammatory cytokines, such as IL-1β
and TNF-α which are considered to play a key role in
inducing sickness behavior during acute illness ([55];
Kelley et al., [56]). In this project we will not only as-
sess cytokine concentrations in blood plasma, but also
evaluate cytokine activity at the mRNA level using
pax-gene tubes. Previous studies on this subject have
met with inconsistent results (Lyall et al., [57]). One
explanation is that cytokines in the body respond to a
variety of external and environmental stimuli like
stress and exercise. To control for such influences, we
will select well-matched controls that will follow
exactly the same procedures during each test day. In
addition, cytokines will not only be measured in blood
plasma, but also at the mRNA level using pax-gene
tubes.
Disturbances in hypothalamic-pituitary-adrenal (HPA)-
axis functioning have been associated with fatigue and
CFS symptoms (Powell et al., [58]; Silverman et al.,
[59]; Tak et al., [60]). More specifically, previous work
shows that CFS patients are characterized by hypo-
cortisolism (Nater et al., [61]a; Nater et al., [62]b),
which can normalize to levels comparable to healthy
population after CBT in adolescents (Nijhof et al., [63];
Rimes et al., [64]) and adults (Roberts et al., [65]). In
this project we will replicate and extend these findings,
by assessing both diurnal cortisol fluctuations in saliva
as well as baseline cortisol levels of the past month in
hair.
Summary
This project aims at investigating neural mechanisms
underlying CFS symptoms and its changes after CBT by
collection anatomical MRI measures, functional MRI
measures, behavioral measures and blood, saliva and hair
sampling. We will extend previous neuroimaging work
by collecting data form a large group of subjects and by
including a patient control condition in a RCT. This
project creates a unique opportunity to enhance our un-
derstanding of CFS symptoms and its change by CBT in
terms of neuroanatomical, neurofunctional, behavioural,
immunological and endocrinological mechanisms.
Methods/design
Study design
A RCT will be conducted to investigate neural correlates
of change brought on by CBT in patients diagnosed with
CFS. CFS patients will be randomly assigned to either
the intervention group (N = 60), which will immediately
start with CBT, or the waiting group (N = 30), which will
start with CBT after a 6 months waiting period. In order
to compare CFS patients that recover from CBT with
those that do not we will use a 2:1 allocation ratio for
CBT and waiting group respectively. MRI measurements,
behavioral measures, questionnaires and biomarker sam-
pling will be gathered at baseline and at a second session
after approximately 6 months in both groups. Results
will be compared to 30 age, gender and education
matched healthy controls, which will also be tested
twice, separated by a 6 months period (Fig. 1).
Ethical aspects
The study is approved by the Medical research ethics
committee and Central Committee on Research Involving
Human Subjects (registration number NL43606.091.13).
This study will be conducted according to the principles
of the declaration of Helsinki. CFS patients will be re-
cruited from the Expert Centre for Chronic Fatigue
(ECCF). Participants will be informed about the study and
written informed consents will be obtained before the first
testing day and randomization.
Participants can withdraw from the study at any time,
and for any reason, without consequences. The investi-
gator can decide to withdraw a participant from the
study in case of late disclosure of exclusion criteria (e.g.
psychiatric co-morbidity) or a change in meeting in- and
exclusion criteria (e.g. when participant decides to start
psychotropic medication after inclusion). CFS patients
who (are) withdraw(n) from the study will continue to
receive treatment at the ECCF. Patients that withdraw
before randomization or did not start face-to-face CBT
when assigned to the CBT condition and participants
that are withdrawn by the investigator will be replaced
when time allows. Patients that received CBT for CFS
outside the ECCF during their waiting list period will be
excluded from analysis.
Study population and recruitment procedure
A total of 90 female CFS patients and 30 age and educa-
tion matched female healthy controls will be recruited
from the ECCF of the radboudUMC in Nijmegen, the
Netherlands. Only female patients are included for
homogeneity. Patients that are referred to the ECCF of
the Radboudumc, are diagnosed with CFS according to
the US Centers for Disease Control and prevention
(CDC) consensus-criteria ([66]; Reeves et al., [2]), and
scoring 40 or higher on the subscale fatigue severity of
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the Checklist Individual Strength (CIS) and have a total
score of 700 or higher on the Sickness Impact Profile 8
(SIP8) will be informed about the study by their treating
psychologist during their first intake session at the
ECCF. If the patients agree, they will receive an informa-
tion folder. The investigator will call the patients after a
one week reflection period to answer any further ques-
tions and to ask for participation. If willing to partici-
pate, and meeting all in- and exclusion criteria (Table 1),
patients will be invited for the first testing day at the
Donders institute for brain cognition and behavior. Age
and education matched female healthy controls will be
recruited though advertisements and through flyers in
the patients folder. Interested healthy controls will re-
ceive an information folder and the recruitment proced-
ure will follow the same steps as described above.
Written informed consent will be given at the first ses-
sion day. Randomization of patients will take place after
the first session day. The Mini-international Neuro-
psychiatric Interview (M.I.N.I) will be used to rule out
any current psychiatric disorders.
Intervention
CBT for CFS (Heins et al., [67]; Wiborg et al., [9]) aims
at recovery, meaning that the CFS patient is no longer
severely fatigued and disabled by the fatigue, by chan-
ging cognitions and behaviors assumed to perpetuate the
symptoms. Previous trials have repeatedly demonstrated
that CBT for CFS leads to a significant reduction of
fatigue and disability ([68]; Prins et al., [69]; White et al.,
[6]; White et al., [70]; Wiborg et al., [9]) and to recovery
in a subset of patients (Knoop et al., [5]; White et al.,
[6]). CBT treatment will be given by trained cognitive
behavioral therapists at the ECCF of the radboudUMC
in Nijmegen, the Netherlands. Treatment consists of
12–14 individual sessions with a trained cognitive behav-
ioral therapist within a period of approximately 6 months.
The treatment starts with explanation of the cognitive
behavioral model of CFS and goal setting. Patients formu-
late their goals in concrete activities they will do when
they are no longer bothered by fatigue, e.g. resumption of
work or study. Then, patients will learn to regulate their
sleep-wake cycle by maintaining fixed bedtimes and no
longer sleep or lie down during the day. Once the
Fig. 1 Trial design. CBT = Cognitive behavioural therapy
Table 1 Inclusion and exclusion criteria
Inclusion criteria
1. Female
2. Age between 18 and 55 years
Additional inclusion criteria for CFS patients
1. CFS diagnosis according to the CDC-criteria ([66]; Reeves et al., [2]);
2. Fatigue severity subscale (CIS) score ≥40
3. Severely disabled, defined by scoring≥ 700 on the Sickness Impact
Profile (SIP)
4. Eligible for treatment with CBT
Additional inclusion criteria for healthy controls
5. Fatigue severity subscale (CIS) score≤ 35
Exclusion criteria
1. Current use of psychotropic medication (e.g. antidepressants)
2. Contra-indication for MR-examinations (e.g. claustrophobia)
3. Abnormal hearing or (uncorrected) vision
4. Insufficient command of the Dutch language to fill out questionnaires,
understand task instructions or perform the neuropsychological tests
5. Restricted function of the right hand that confounds handgrip
performance for the fMRI tasks
Additional exclusion criteria for healthy controls
6. Current psychological or psychiatric disordera,b
7. (History of) alcohol or substance abusea
8. Severe obesity (BMI≥ 40)a
9. Chronic disease or pain condition (e.g. rheumatoid arthritis)
10. Current acute pain condition
athese criteria are part of the CDC criteria for CFS
bas revealed by the Mini International Neuropsychiatric Interview (M.I.N.I.)
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sleep-wake cycle is regulated, patients will start with a
graded activity program consisting of a graded increase
in walking of cycling activities. Based on their physical
activity patterns, relative active patients will first learn
to better divide activities across the day before starting
with the graded activity program and low active
patients will start directly with the graded activity
program. Dysfunctional fatigue-related cognitions, e.g.
catastrophising in response to fatigue, low self-efficacy
and increased focus on symptoms are challenged con-
tinuously throughout the intervention. When activity
levels are increased and patients attain the belief that
they have potential to be more active, they start with
realization of their prior set goals. The last part of the
intervention aims at reappraisal of fatigue as a normal
sensation and prevention of relapse.
Outcome measures
Primary clinical outcome measures
Fatigue severity will be measured using the subscale
fatigue severity of the CIS consisting of 8 items scored
on a 7-point Likert Scale with a total score ranging be-
tween 8–56 (Vercoulen et al., [71]). Higher scores indi-
cate higher levels of fatigue. This questionnaire has been
validated extensively in patients with CFS ([72, 73];
Vercoulen et al., [71]; Vercoulen et al., [42]). Following
previous reports (Prins et al., [69]; Wiborg et al., [10])
we will use cut-off score of ≥ 40 for inclusion of severely
fatigued CFS patients.
Successful treatment is defined by a clinically signifi-
cant improvement on the CIS sub-scale fatigue severity,
i.e. scoring lower than 35 and a reliable change index of
>1.96 on the CIS subscale fatigue (Knoop et al., [74]).
The cut-off score of 35 has frequently been used as a cri-
terion to indicate clinically relevant fatigue in clinical
studies (Knoop et al., [5]; Wiborg et al., [75]).
Functional impairment will be measured in CFS pa-
tients using the Sickness Impact Profile 8 [76]. The SIP8
contains 85 statements about health-related dysfunction
in 8 areas domains (home management, ambulation,
mobility, intellect, social interactions, sleep/rest behav-
iour, recreation and work). In completing the SIP, the
patient is asked to check only those statements that she
is sure describe her on a given day and are related to her
health. The eight subscales are added to provide one
weighted score of disability (SIP8 total, range 0–5799)
(Knoop et al., [5]; Prins et al., [69]; Wiborg et al., [9]).
Higher scores indicate higher levels of experienced dis-
abilities. Functional impairment will be defined as a SIP
score higher than 700.
Secondary clinical measures
Fatigue related cognitions and behaviours, physical and
social functioning are assessed using questionnaires as
part of the clinical routine of the ECCF. A selection of
these questionnaires will also be assed in the healthy
control group and include the RAND-36 (Stewart et al.,
[77]; Ware and Sherbourne, [78]), the Beck depression
Inventory (BDI) [79], the Symptom Checklist 90 (SCL-90)
(Arrindell and Ettema, [80]), the Fatigue Quality List
(KWAMOE) [81], the self efficacy scale fatigue (SES)
(Prins et al., [69]; Vercoulen et al., [71]; Wiborg et al., [9])
and the Adjusted Physical Activities Rating Scale (PARS)
(Vercoulen et al., [82]). In addition, the attention Control
Scale questionnaire (ACS)(Derryberry and Reed, [83]) will
be assessed in all subjects. During each test day, state
changes in fatigue and mood will be assessed using the
profile of moods (POMS) questionnaires (McNair et al.,
[84]) at 3 time points in both patients and healthy
controls.
Physical activity
Previous work in both humans[85] and animals (Praag,
[86]) suggest a possible link between physical exercise
and neurogenesis. Accordingly, given that graded in-
crease of physical activity levels is an important part of
the CBT program, we will also assess physical activity
levels. As in the previous reports [13, 14], physical activ-
ity levels will be assessed in all participants, over a
period of two weeks preceding both test sessions using
an actometer. The actometer is a motion-sensitive de-
vice, worn at the ankle, which can register and quantify
human physical activity (Werf et al., [44]).
Neuropsychological testing
To be able to replicate previous reported correlations
between grey matter volume changes and neuropsycho-
logical performance [14] we will assess two tasks of
cognitive speed: the digit symbol substitution test of the
Dutch Wechsler Adult Intelligence Scale (Stinnissen J
et al., [87]) and a choice reaction time task ([14];
Vercoulen et al., [42]). Additionally, working memory
capacity will be assessed with the digit span of the Dutch
Wechsler Adult Intelligence Scale (Groth-Marnat, [88];
Stinnissen J et al., [87]) and intelligence/education level
will be determined with the Dutch adult reading test
(Schmand et al., [89]).
Structural neuroimaging measures
To investigate changes in brain anatomy and metabolism,
several MR-measurements will be obtained on a 3-Tesla
SIEMENS MAGNETON skyra MRI scanner. To investi-
gate global and regional grey and white matter changes
high resolution anatomical images will be obtained using
a T1 weighted magnetization-prepared rapid gradient-
echo (MP-RAGE) sequence (TR\TE: 2300\3.03 ms, flip
angle = 8°, 192 sagittal slices, FoV: 256 × 256 mm, voxel-
size: 1 mm3, slice thickness: 1.00 mm). To investigate the
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microstructural properties of white matter pathways
in the brain, diffusion tensor imaging (DTI) scans will
be assessed (TR = 8200 ms, TE = 89.0 ms, voxel size:
2.2 × 2.2 × 2.2 mm, FOV 220 mm, 64 slices, slice
thickness: 2.2 mm). Brain metabolite changes will be
assessed using single voxel proton magnetic resonance
spectroscopic (MRS) imaging (TR = 1500 ms, TE = 30 ms,
and 64 averages). MRS spectra will be obtained from two
voxels (10 × 20 × 30 mm): One voxel placed in the left
middle frontal gyrus, corresponding to the previous re-
ported region of CBT-associated grey matter changes in
CFS patients [14] and one voxel placed in the left calcarine
gyrus (i.e.primary visual cortex) to assess regional specifi-
city of the changes.
Functional MRI
To explore task-dependent functional MRI will be
assessed using a multi echo, T2*-weighted, gradient-echo
planar imaging (EPI) sequence (TR = 2190 ms, TE = 9.0/
19.28/29.56/39.84 ms, flip angle = 90°, 36 axial slices
aligned with AC-PC plane, slice-matrix size = 64 × 64,
slice thickness = 3.0 mm, slice gap = 0.3 mm, FOV =
212*212 mm). Two different tasks will be employed.
With the first task, we will assess alterations in brain
activation patterns in anticipation of effortful physical
exertions and in response to task-feedback about these
exertions. Participants are instructed to prepare and
then squeeze quickly in a hand grip up to a certain level
indicated by a cue. Cues will indicate to squeeze 30, 50
or 70 % of their maximal voluntary contraction (MVC).
MVC will be calibrated before and after the task to
assess (change in) physical ability. Subjective experience
of fatigue and effort will be assessed before and after the
task. Visual feedback is provided after the squeeze and
will indicate whether the squeeze was “correct”, “too
little” or “too much”. Neural outcome measure is the
Blood Oxygen Level Dependent (BOLD) contrast
during task performance. Behavioral output is the
squeezed force. We will assess the hypothesis that,
compared with healthy controls, CFS patients will
show alterations in neural response to “too much” and
“too little” and that these alterations will vary as a
function of effort level. We expect that these alter-
ations will normalize after successful treatment. In
addition, neural responses during effort anticipation
will be explored.
With the second task, we will assess alterations in
neural activation patterns during effort avoidance learn-
ing using an adapted version of the salience attribution
task (Roiser et al., [52]; Roiser et al., [53]). In this task
participants learn to reduce the effort level of handgrip
contractions by responding sufficiently quickly to a tar-
get presented after a cue. The cues have two dimensions
(shape and color) that provide information about the
probability of the occurrence of the effortful handgrip
contractions. One dimension is predictive for the out-
come, signaling the occurrence of the effortful handgrip
contractions with 80 % and 20 % certainty. The other di-
mension is non-predictive for the outcome, signaling the
occurrence of the effortful handgrip contractions with
50 % certainty for both cues. When effortful outcomes
occur, the required effort level of the handgrip contrac-
tion is reduced as a function of reaction time to the tar-
get. Thus, the faster the subject responds to the target,
the lower the effort level. Neural outcome measure is
the Blood Oxygen Level Dependent (BOLD) contrast
during task performance. Explicit and implicit avoidance
learning will be assessed using cue ratings assessed
after the task, and response reaction times, respect-
ively. Adaptive avoidance learning is defined by higher
neural responses, faster reaction times and higher ex-
plicit ratings for high relative to low predictive cues.
Non-adaptive avoidance learning is defined by larger
differential neural responses, reaction times and expli-
cit ratings for the two non-predictive cue dimensions.
We will assess whether CFS patients will show increased
adaptive and/or non-adaptive avoidance learning com-
pared to healthy controls and whether this normalizes
after CBT.
Task independent-neuroimaging will be used to ex-
plore alterations in neural networks during rest that may
underlie CFS symptoms and CBT effects. A 5 minute
resting state scan will be obtained to explore task-
independent functional connectivity patterns using a
multi echo T2*-weighted, gradient-echo planar imaging
(EPI) sequence (TR = 2000 ms, TE = 9.0 ms, flip angle =
90°, voxel size = 3.3 × 3.3 × 3.3 mm, slice thickness:
3.0 mm). During the scan, the room will be completely
dark and subjects are asked to lie still with their eyes
open to avoid falling asleep.
Behavioral task
We will use a behavioral version of the moving dot para-
digm ([90]; Rahnev et al., [54]) to investigate the influence
of expectancy cues on perceptual decisions. Subjects are
presented with motion of white dots and are requested to
indicate the direction of movement with a button press
(i.e. left or right). Moving dots are presented using three
coherence levels, determined by subjects’ accuracy level
during a preceding training session. Prior to each stimulus
subjects are presented with the words “LEFT” or “RIGHT”
indicating the direction of motion with 75 % accuracy or
with the non-informative word “NEUTRAL”. After each
trial feedback is given by changing the colour of the
fixation point to green (correct) or red (incorrect).
Behavioural outcome measures are the direction of
the movement indicated by the participant and reac-
tion times. As described by ([90]; Rahnev et al., [54]),
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subjects’ hit rates will be used to calculate individual
stimulus discrimination sensitivity (d’) and bias towards
the cued direction (c). Following Edwards model (see
introduction) we will test the hypothesis that CFS patients
show a larger bias towards the cued direction compared
to healthy controls and whether this changes following
CBT.
Citokines and cortisol
Circulating cytokine concentrations will be determined
in blood-plasma using a commercial multiplex assay.
Using pax-gene tubes, cytokine mRNA concentrations
will be measured. The latter will give more insight into
upstream regulation of local cytokine production. Corti-
sol concentrations will be determined from saliva and
hair. We will measure both daily variations of cortisol
levels (i.e. cortisol awakening response) in saliva as well
as baseline cortisol levels of the past month in hair.
Blood and hair samples will be assessed on each test
day. Saliva will be collected at home during two con-
secutive weekdays within two weeks prior to or after
each test day. Saliva samples will be taken at 4 different
time points during a day: directly after waking, 30 mi-
nutes after waking, around 11.00 a.m. or at least 1 hour
after the second sampling and around 08.00 p.m. Cyto-
kine and cortisol concentrations will be compared be-
tween CFS and HC and before and after CBT or waiting
list.
Session procedure
Participants will be invited to the Donders institute for
brain cognition and behavior on two session days separated
by approximately 6 months. Each session will include the
following procedures: (1) hair and blood sampling. (2) prac-
tice of fMRI tasks, including the calibration of MVC for the
two fMRI tasks. The practice session is done in a dummy
scanner to ensure same body position during handgrip-
calibration, practice and fMRI-scanning. (3) MRI scanning,
including six scans and a 15 minute break: structural MRI,
fMRI during task1, MRS, break, fMRI during task2, DTI
and resting state. (4) Behavioral and neuropsychological
testing. The order is kept the same across subjects and
sessions. An overview of a session day is given in Fig. 2.
Written informed consent is given on the first session day.
Trait measures such as the adult reading test are only
assessed on the first test day. POMS measurements are
assessed before sampling, during the break and after be-
havioral testing. The total duration of each session will be
about 5 hours. For CFS patients, questionnaires are
assessed as part of the clinical routine of the ECCF prior
to the session days. For healthy controls, questionnaires
are assessed at home through an internet link, sent to the
subjects by email.
Analysis
The aim of this project is to explore the neural mecha-
nisms of change underlying (successful) CBT for CFS.
Fig. 2 Flowchart of fMRI session day. MVC =Maximal voluntaty contraction, MRI = Magnetic resonance imaging, fMRI = functional MRI
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Accordingly, we will include all patients that completed
both sessions for analysis of CBT effects. Statistical ana-
lysis will be done to 1) compare outcome measures
between CFS patients and healthy controls at baseline,
2) compare changes between baseline and second assess-
ment between patients that had CBT and waiting list
and 3) compare changes between baseline and second
assessment between CFS patients within the CBT condi-
tion that show clinical significant improvement (see
above) and those that do not. Following previous reports
[13, 14], relationship between neural outcome measures
and clinical outcome measures, physical activity levels
and neuropsychological functioning will be assessed.
Multiple mediation analyses will be conducted to ex-
plore whether neural outcome measures mediate therapy
effects on clinical outcome measures (Preacher and
Hayes, [91]).
Sample size
Power calculation is based on current standards in
neuroimaging. For (f )MRI, the recommended number of
subjects for between-group designs is 20 (Thirion et al.,
[92]). In addition, from previous studies we know that
groups of 20 subjects per condition are sufficient to
detect significant differences in (neuro) physiological pa-
rameters measured with fMRI [17, 18]. Similarly, a group
of 22 subjects were sufficient to detect significant treat-
ment effects measured with MRI [13]. Based on previous
work at the ECCF (Knoop et al., [5]) it is assumed that
approximately 50 % of the CFS patients in the CBT con-
dition will show significant improvement (for definition:
see above). Accordingly, to be able to compare success-
fully treated patients with non-successfully treated pa-
tients we will include twice as many patients in the CBT
condition as in the waiting list condition. Assuming that
10 % of the measurements (from baseline as well as 2nd
assessment) will yield technically insufficient data, 17 %
of the patients will drop out from the study and a ratio
of 2:1 (CBT: waiting list), we will include 30 healthy con-
trols, 30 patients in the waiting list condition and 60 pa-
tients in the CBT condition (Fig. 3). Based on previous
clinical work (Knoop et al., [74]; Wiborg et al., [9]), we
Fig. 3 Flowchart of inclusion. CFS = Chronic fatigue syndrome, CBT = Cognitive behavioural therapy
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expect a mean decline of–15.2 (±15.8) for patients in the
CBT condition and–5.2 (±7.2) for patients in the waiting
list condition. Accordingly, assuming an alfa of 0.05 and
a power of 0.95 this will also yield enough power to rep-
licate previous reported treatment effects on the primary
clinical outcome measures. Note that technical failure of
MRI measurements will not affect the collection of
clinical measures.
Randomization
CFS patients will be randomized to either the CBT
condition (66 %) or waiting list condition (33 %).
Randomization will take place per patient after the first
session day in the presence of the therapist and patient,
either during the second diagnostic appointment with
the therapist or during a phone call with the therapist.
Randomization will be done by supporting staff of the
ECCF who are not directly involved in the study. Con-
cealed allocation will be guaranteed by using a central
web-based randomization program, developed by an in-
dependent statistical advisor. Patients randomized to the
intervention group will start treatment directly and will
be treated with CBT for CFS (see above). Patients
randomized to the control group will start with CBT for
CFS 6 months later, after the second assessment. The
researchers that will collect and analyze the data are not
blind to the allocation, because knowledge of treatment
progress is necessary for the planning of the second test
day.
Discussion
This study will investigate neural mechanisms under-
lying CFS symptoms and its changes after CBT. The
aims are threefold. First, we will replicate and extend
previously found anatomical findings, second, we will
explore underlying neural mechanisms using functional
neuroimaging and third, we will collect biomarker mea-
sures from blood, hair and saliva to assess cytokine and
cortisol changes during CBT.
To our knowledge, this will be the first randomised
controlled trial investigating neural mechanisms of
change brought on by CBT for CFS. There are a limited
number of studies that investigated neural changes after
CBT in CFS [14] or CBT in other disorders (Seminowicz
et al., [93]). However, those studies often relied on small
samples (<20) and seldom used a no-treatment patient
control condition. Here we overcome those problems by
collecting data of more patients and by including a wait-
ing list control condition. Because we will include twice
as many patients in the CBT condition as in the waiting
list condition, this study will allow us not only to investi-
gate changes between CBT and waiting list conditions,
but also to investigate changes within the CBT group
between those patients that benefit from CBT and those
that do not. This creates a unique change to investigate
the neural mechanisms of change of CBT and to identify
biomarkers that may predict treatment outcome.
We aim to replicated previously found anatomical
findings [13, 14] and extend these findings with add-
itional anatomical information using MRS and DTI.
With respect to functional neuroimaging and behavioral
assessment, task selection and hypotheses are based on a
combination of clinical observations, cognitive behavioral
models of CBT and a recent neurobiologically informed
Bayesian model of medically unexplained symptoms. This
translation between clinical observations and fundamental
neuroscience models is unique in the investigation of CFS
and an important step forward in understanding the
etiology of CFS symptoms and the mechanisms of change
of CBT.
Taken together, this project creates a unique oppor-
tunity to enhance our understanding of CFS symptoms
and its change by CBT in terms of neuroanatomical,
neurofunctional, behavioural, immunological and endo-
crinological mechanisms. Moreover, the comparison of
patients that benefit from CBT with those that do not
may lead to new insights for treatment resistant CFS
patients.
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